GLP-1 and metabolic medicine in 2026: a crash course
A sourced crash course on GLP-1 drugs: incretin biology, semaglutide, tirzepatide, pills and triple agonists, outcome trials, prices and coverage.
GLP-1 and metabolic medicine
GLP-1 drugs and the new science of obesity, diabetes and metabolic disease.
GLP-1 and metabolic medicine tracker
Live tracker of GLP-1 and obesity-medicine milestones: approvals, pills, triple agonists, outcome trials, Medicare coverage and pricing, 2023–2026.
Obicetrapib
PCSK9 inhibitors
Statins
Cholesterol and fasting research tracker 2026
Does intermittent fasting work? RCTs vs observational studies
Cholesterol explained: LDL, HDL, triglycerides and the 2026 guideline
Cholesterol-lowering drugs: statins, PCSK9, Lipfendra and more
Home cholesterol tests: a sourced buyer's guide (2026)
Intermittent fasting explained: 16:8, 5:2 and what trials show
Lipoprotein(a) explained: the inherited cholesterol risk
CagriSema (cagrilintide and semaglutide)
Eli Lilly and Company
Novo Nordisk
Orforglipron (Foundayo)
Retatrutide
Semaglutide
Tirzepatide
Who gets GLP-1 drugs? The 2026 price and coverage debate
Lifelong GLP-1s? The debate over long-term use
GLP-1 outcome trials explained: heart, kidney, liver and beyond
How GLP-1 drugs work
Obesity as a chronic disease